Bone Marrow-on-Chip as smart sensor of lung cancer relapse

BuonMarrow aims to develop an innovative in vitro device using bone marrow mesenchymal stromal cells to early detect lung cancer relapse, enhancing personalized treatment and patient survival.

Subsidie
€ 2.999.835
2024

Projectdetails

Introduction

In the past 40 years, the overall survival rate for people affected by tumors has doubled, with about 50% of patients now surviving their disease for 10 years or more. Nonetheless, some cancers (e.g., lung cancer) still have a poor survival rate.

Problem Statement

A major cause of lung cancer mortality is represented by disease relapse, occurring when few of the original cancer cells survive the initial treatment, causing primary tumor recurrence. Currently, no options are available to predict the risk of lung cancer relapse, which is only diagnosed late based on radiological evidence.

Urgent Need

Hence, the ability to early detect lung cancer relapse represents an urgent and unmet need, since a fast and tailored treatment could dramatically increase patients’ survival rate.

Project Hypothesis

BuonMarrow lays on the groundbreaking hypothesis, supported by our Consortium preliminary clinical evidence, that bone marrow mesenchymal stromal cells (BM-MSC) may be educated upon cancer mediators exposure and acquire a long-term memory-like response, which is amplified when exposed to a secondary tumor.

Technological Approach

Owing to breakthrough technologies available in the Consortium, including:

  • Organ-on-chip
  • Innovative optical sensors
  • Biological modeling of the bone marrow niche

BuonMarrow partners will develop an in vitro miniaturized bone marrow device able to harness the amplified BM-MSC response generated by liquid biopsy of lung cancer patients, thus acting as a biological sensor for the early detection of relapse.

Research Methodology

A combination of retrospective and prospective clinical studies will allow us to:

  1. Calibrate the sensor
  2. Validate the sensor

This will deliver an unprecedented tool to assist the decision-making process for lung cancer patients.

Expected Impact

We expect to significantly improve oncological treatments, building on a personalized medicine approach to increase patient survival and well-being, thereby deeply impacting the EU’s socio-economic environment.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.999.835
Totale projectbegroting€ 2.999.835

Tijdlijn

Startdatum1-3-2024
Einddatum28-2-2027
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • POLITECNICO DI MILANOpenvoerder
  • FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
  • LUNDS UNIVERSITET
  • FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Land(en)

ItalySpainSweden

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"

The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.

€ 2.996.550
EIC Pathfinder

Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.

The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.

€ 2.744.300
EIC Pathfinder

Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures

Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.

€ 2.552.277
EIC Pathfinder

Emerging technologies for crystal-based gamma-ray light sources

TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.

€ 2.643.187

Vergelijkbare projecten uit andere regelingen

ERC COG

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.

€ 1.993.875
EIC Transition

Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)

Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.

€ 1.881.875
ERC STG

Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovation

META-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time.

€ 1.499.884
ERC POC

Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD

The ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors.

€ 150.000